| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/EN.140.1.244 |
| P698 | PubMed publication ID | 9886831 |
| P50 | author | Anthony P Goldstone | Q43185452 |
| P2093 | author name string | S R Bloom | |
| M A Ghatei | |||
| M Rossi | |||
| S J Choi | |||
| S Abusnana | |||
| D O'Shea | |||
| C M Edwards | |||
| K Meeran | |||
| G M Taylor | |||
| C J Small | |||
| D Sunter | |||
| M M Heath | |||
| I Gunn | |||
| M D Turton | |||
| J Steere | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 244-250 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | Endocrinology | Q3054009 |
| P1476 | title | Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. | |
| P478 | volume | 140 |
| Q33338102 | Anorectic brainstem peptides: more pieces to the puzzle |
| Q30354242 | Antiobesity pharmacotherapy: new drugs and emerging targets |
| Q51744991 | Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption. |
| Q37508420 | Bowels control brain: gut hormones and obesity |
| Q36796571 | Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation |
| Q24601868 | Central and Peripheral Administration of Secretin Inhibits Food Intake in Mice through the Activation of the Melanocortin System |
| Q38784664 | Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system |
| Q37212333 | Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides |
| Q35584701 | Controversies surrounding high-protein diet intake: satiating effect and kidney and bone health. |
| Q30399390 | Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity |
| Q37429168 | Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats |
| Q39701090 | Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model |
| Q47868205 | Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity |
| Q36415844 | Divergent leptin signaling in proglucagon neurons of the nucleus of the solitary tract in mice and rats |
| Q36801981 | Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2. |
| Q33737073 | Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults |
| Q34620465 | Emerging role of GLP-1 receptor agonists in the treatment of obesity |
| Q36240979 | Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes |
| Q40694884 | Endogenous Glucagon-like Peptide-1 Suppresses High-Fat Food Intake by Reducing Synaptic Drive onto Mesolimbic Dopamine Neurons |
| Q34614609 | Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats. |
| Q37210752 | Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling |
| Q38370064 | Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia |
| Q24629441 | Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice |
| Q34745109 | Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. |
| Q37885717 | GLP-1 and energy balance: an integrated model of short-term and long-term control |
| Q92237072 | GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats |
| Q38040314 | GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus |
| Q27000749 | GLP-1, the gut-brain, and brain-periphery axes |
| Q90016044 | GLP-1: Molecular mechanisms and outcomes of a complex signaling system |
| Q34758871 | Gastric inhibitory polypeptide: the neglected incretin revisited |
| Q24669951 | Gastrointestinal hormones regulating appetite |
| Q37047199 | Gastrointestinal peptides controlling body weight homeostasis. |
| Q28581928 | Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling |
| Q47174979 | Glucagon-like peptide 1 and pancreatic polypeptide responses to feeding in normal weight and overweight children |
| Q34635520 | Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives |
| Q45061870 | Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal. |
| Q28084873 | Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling |
| Q37686556 | Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection |
| Q42176081 | Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons |
| Q35601526 | Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake |
| Q42936904 | Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight |
| Q30353952 | Glutamatergic phenotype of glucagon-like peptide 1 neurons in the caudal nucleus of the solitary tract in rats |
| Q36452530 | Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism |
| Q35796674 | Gut hormones in the control of appetite |
| Q36455914 | Gut peptides and the regulation of appetite. |
| Q37142459 | Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt. |
| Q34506664 | Human monoclonal antibodies against glucagon receptor improve glucose homeostasis by suppression of hepatic glucose output in diet-induced obese mice |
| Q36979291 | Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. |
| Q37892968 | Hypothalamic control of energy and glucose metabolism |
| Q35690970 | Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose |
| Q48719407 | Interaction of corticotropin-releasing factor and glucagon-like peptide-1 on behaviors in chicks |
| Q35601262 | Jejunal linoleic acid infusions require GLP-1 receptor signaling to inhibit food intake: implications for the effectiveness of Roux-en-Y gastric bypass |
| Q88732200 | Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons |
| Q30924982 | Liraglutide and obesity: a review of the data so far. |
| Q34281599 | Measurement of ad libitum food intake, physical activity, and sedentary time in response to overfeeding |
| Q37244738 | Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. |
| Q37569030 | Molecular neuroendocrine targets for obesity therapy |
| Q33579205 | Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats |
| Q38197775 | Neural integration of satiation and food reward: role of GLP-1 and orexin pathways. |
| Q43635126 | Neuropeptide regulation of feeding in catfish, Ictalurus punctatus: a role for glucagon-like peptide-1 (GLP-1)? |
| Q30429816 | New advances in models and strategies for developing anti-obesity drugs |
| Q36923698 | Nucleus accumbens GLP-1 receptors influence meal size and palatability. |
| Q33827988 | Obesity pharmacotherapy: what is next? |
| Q89715710 | One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer |
| Q35640531 | Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. |
| Q48344210 | Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. |
| Q42997344 | Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes |
| Q33945287 | Pharmacology of appetite suppression. |
| Q38016154 | Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor |
| Q59812434 | Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function |
| Q30939844 | Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data |
| Q36759089 | Pro-protein convertases in intermediary metabolism: islet hormones, brain/gut hormones and integrated physiology |
| Q55039236 | Protein-induced satiation and the calcium-sensing receptor. |
| Q30403705 | Regulation of appetite to treat obesity |
| Q35766237 | Role of gastrointestinal hormones in feeding behavior and obesity treatment |
| Q37708356 | Role of the glucagon-like-peptide-1 receptor in the control of energy balance |
| Q50233425 | Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial |
| Q36439654 | Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4 |
| Q42492321 | Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice |
| Q24311416 | TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta |
| Q48052616 | The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice |
| Q28216072 | The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness |
| Q37343491 | The effects of GLP-1 infusion in the hepatic portal region on food intake |
| Q28598004 | The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents |
| Q35181801 | The glucagon-like peptides: a double-edged therapeutic sword? |
| Q38146179 | The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? |
| Q33776092 | The incretin system and cardiometabolic disease |
| Q36724837 | The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q33570118 | Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults |
| Q40691546 | Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells |
| Q35639940 | Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain |
| Q34635474 | Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides |
Search more.